Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Pignata S, Bookman M, Sehouli J, Miller A, Penson RT, Taskiran C, Anderson C, Hietanen S, Myers T, Madry R, Willmott L, Lortholary A, Thomes-Pepin J, Aghajanian C, McCourt C, Stuckey A, Wu X, Nishio S, Copeland LJ, He Y, Molinero L, Patel S, Lin YG, Khor VK, Moore KN. Pignata S, et al. Among authors: madry r. Gynecol Oncol. 2023 Oct;177:20-31. doi: 10.1016/j.ygyno.2023.06.018. Epub 2023 Aug 23. Gynecol Oncol. 2023. PMID: 37625235 Free PMC article. Clinical Trial.
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Pignata S, Oza A, Hall G, Pardo B, Madry R, Cibula D, Klat J, Montes A, Glasspool R, Colombo N, Pete I, Herrero Ibáñez A, Marín MR, Ilieva R, Timcheva C, Di Maio M, Blakeley C, Taylor R, Barnicle A, Clamp A. Pignata S, et al. Among authors: madry r. Gynecol Oncol. 2023 May;172:121-129. doi: 10.1016/j.ygyno.2023.03.019. Epub 2023 Apr 6. Gynecol Oncol. 2023. PMID: 37030280 Free article.
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
Scambia G, Villalobos Valencia R, Colombo N, Cibula D, Leath CA 3rd, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Ah-See ML, Lowe ES, Lukashchuk N, Carter D, Penson RT. Scambia G, et al. Among authors: madry r. J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933. Online ahead of print. J Clin Oncol. 2024. PMID: 39668137
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A; OReO/ENGOT-ov38 investigators. Pujade-Lauraine E, et al. Among authors: madry r. Ann Oncol. 2023 Dec;34(12):1152-1164. doi: 10.1016/j.annonc.2023.09.3110. Epub 2023 Oct 4. Ann Oncol. 2023. PMID: 37797734 Free article. Clinical Trial.
Epithelial Ovarian Cancer-Varied Treatment Results.
Millert-Kalińska S, Przybylski M, Pruski D, Stawicka-Niełacna M, Mądry R. Millert-Kalińska S, et al. Among authors: madry r. Healthcare (Basel). 2023 Jul 17;11(14):2043. doi: 10.3390/healthcare11142043. Healthcare (Basel). 2023. PMID: 37510484 Free PMC article.
Uterine sarcoma - time is worth its weight in gold.
Pruski D, Millert-Kalińska S, Mądry R, Kotynia K, Pawełek T, Rusek D, Zmaczyński A, Jach R, Przybylski M. Pruski D, et al. Among authors: madry r. Pol J Pathol. 2023;74(1):59-62. doi: 10.5114/pjp.2023.127292. Pol J Pathol. 2023. PMID: 37306355 Free article.
67 results